Diagnosis of acute promyelocytic leukemia (APL M): t(;)(q;q); (promyelocytic leukemia [PML]/retinoic acid receptor [RAR] alpha [a]) and variants excluded.
Acute promyelocytic leukemia with PML-RARA or t(;)
Acute promyelocytic leukemia (APL) with t(;)(q;q) PML-RARA
Diagnosis acute promyelocytic leukemia (APL) with t(;)(q;q); promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA)
Patient with documented acute promyelocytic leukemia (PML) and/or PML- retinoic acid receptor (RAR) transcript
Subjects with French American British (FAB) M (t (; ) (q; q) [promyelocytic leukemia (PML)-retinoic acid receptor (RAR) alpha]) are not eligible
Diagnosis of acute promyelocytic leukemia (APL, French-American-British [FAB] classification M or WHO classification of APL with t (;)(q;q), promyelocytic leukemia protein [PML]/retinoic acid receptor alpha [RARa] and variants)
Patients with acute promyelocytic leukemia (APL) confirmed either by the presence of t(;)(q;q) or promyelocytic leukemia (PML)/retinoic acid receptor (RAR) alpha transcripts will be excluded
The diagnosis of AML-M (acute promyelocytic leukemia) characterized by translocations involving the retinoic acid receptor-alpha (RAR-alpha) gene
Acute promyelocytic leukemia with t(;)(q;q) and/or PML-RARA molecular rearrangement
Patients with relapsed/refractory disease must have morphologic proof (from bone marrow aspirate, smears or touch preps of bone marrow biopsy) of AML with >= % blasts within two weeks ( days) prior to initiation of therapy\r\n* All immunophenotype and cytogenetic/molecular groups are eligible for participation except for acute promyelocytic leukemia (APL) (as proven by the presence of promyelocytic leukemia/retinoic acid receptor alpha [PML-retinoic acid-receptor-[RAR] alpha])
Subjects with acute promyelocytic leukemia (APL) - French-American-British Cooperative group (FAB) M (t(;)(q;q)[promyelocytic leukemia (PML)-retinoic acid receptor (RAR)]) are not eligible
Previously untreated patients with a morphologic diagnosis of APL, confirmed by demonstration of t(;) using conventional cytogenetics OR fluorescence in situ hybridization (FISH), OR a positive reverse transcriptase (RT)-polymerase chain reaction (PCR) assay for promyelocytic leukemia (PML)-retinoic acid receptor, alpha (RAR-alpha) at the subject's local institution
Diagnosis of acute promyelocytic leukemia (APL, French-American-British [FAB] classification M or World Health Organization [WHO] classification of APL with t[;][q;q]), (progressive multifocal leukoencephalopathy [PML]/retinoic acid receptor alpha [RARa] and variants)
Acute promyelocytic leukemia with t(;), or its molecular equivalent (PML-RARalpha)
The patient has acute promyelocytic leukemia with t(;) (q;q), (PML/RAR?) or variants.
The patient has acute promyelocytic leukemia with t(;)(q;q), (PML/RAR?) or variants.
Acute promyelocytic leukemia (APL) with PML-RARA
Diagnosis of MDS or AML other than APL with t(;)(q;q), (promyelocytic leukemia[PML]/retinoic acid receptor [RAR]), or variants according to the  World Health Organization (WHO) classification
